89581-58-8 Usage
General Description
BUTTPARK 153\57-36 is a chemical compound primarily used as an antioxidant and stabilizer in the production of various materials such as plastics, rubber, and adhesives. It is a mixture of different organic compounds, including various phenolic compounds and fatty acid amides. It helps prevent the degradation of these materials caused by exposure to heat, light, or oxygen, thereby extending their shelf life and improving their performance. Additionally, BUTTPARK 153\57-36 can also be used as an antioxidant in food packaging and as a stabilizer in the production of lubricants and fuels. Overall, it plays a crucial role in preserving the quality and integrity of various materials and products.
Check Digit Verification of cas no
The CAS Registry Mumber 89581-58-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,5,8 and 1 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 89581-58:
(7*8)+(6*9)+(5*5)+(4*8)+(3*1)+(2*5)+(1*8)=188
188 % 10 = 8
So 89581-58-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H5ClN2O2/c1-3-2-4(5(10)11)9-6(7)8-3/h2H,1H3,(H,10,11)
89581-58-8Relevant articles and documents
SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA
-
Page/Page column 155-156, (2022/01/05)
Disclosed are compounds that are chemical inhibitors of SOX11. The compounds disclosed are useful in treatment of various cancers.
NOVEL PYRIMIDINE DERIVATIVES
-
Page/Page column 12, (2010/09/18)
The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)
IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
-
Page/Page column 130-131, (2010/01/07)
The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
